Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc. for $85 million on January 4, 2023. OriCiro team will join Moderna.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124.1 USD | -0.87% |
|
+5.63% | +24.74% |
07-17 | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
07-15 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B | |
-5.60% | 11.71B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna, Inc. entered into a definitive agreement to acquire OriCiro Genomics, Inc. for $85 million.